Please assess the completion status of the following clinical trial:

Trial Title: [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Part 1 and Part 2:~* Male, or non-pregnant and non-breast feeding female; in addition:~  * Male participant who is sexually active with females of childbearing potential must be willing to use a condom from the first dose of study drug until 3 months post the last dose of study drug~ * Female participant with reproductive potential must have serum β-human chorionic gonadotropin (β-hCG) test result consistent with non-pregnant state at screening and agree to use two acceptable methods of birth control beginning at screening visit, during study and until 2 weeks after the last dose of study drug~ * Post-menopausal female participant has been without menses for at least 1 year and has a documented follicle stimulating hormone (FSH) level in the postmenopausal range at screening~ * Surgically sterile female participant may enroll in study if procedure (hysterectomy, oophorectomy, or tubal ligation) is documented/confirmed by medical records or protocol-defined examination/tests~* Nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 3 months~Part 1 only:~* 18 to 55 years of age~* Body Mass Index (BMI) between 18-32 kg/m\^2~* In good health based on medical history, physical examination, vital sign measurements, electrocardiogram (ECG) and laboratory safety tests~Part 2 only:~* 56 to 85 years of age~* Body weight \<136 kg~* In stable medical condition based on medical history, physical examination, vital sign measurements and ECG~* In good health based on laboratory safety tests~* For some participants, willing to allow placement of an arterial catheter in the radial artery~* For AD participants:~  * Mini-Mental State Examination (MMSE) score ≤28~ * Meets National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD~ * Meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for AD~ * Modified Hachinski score ≤4~ * Screening magnetic resonance imaging (MRI) scan consistent with a diagnosis of AD~ * Able to read at a 6th grade level or equivalent and has a history of academic achievement and/or employment sufficient to exclude mental retardation~ * Has a reliable informant/caregiver who is able to accompany the participant to all clinic visits and provide information to study investigator/staff via telephone contact~ * If taking symptomatic treatment for AD, be on a stable dose for at least 4 weeks prior to study~* For amnestic MCI participants:~  * MMSE score ≥26~ * A history of subjective memory decline before screening~ * Objective impairment in verbal memory based on investigator's clinical assessment~ * General cognitive function and activities of daily living sufficiently intact, so as not to meet criteria for mild AD dementia~ * Modified Hachinski score ≤4~ * MRI scan obtained at the screening visit is either normal or consistent with a diagnosis of AD~ * Able to read at a 6th grade level or equivalent and has a history of academic achievement and/or employment sufficient to exclude mental retardation~* For non-AD/non-MCI healthy elderly participants:~  * MMSE score ≥27~ * No history of subjective memory or other cognitive complaints~ * No objective evidence of memory or cognitive impairment~Exclusion Criteria:~Part 1 and Part 2:~* Subject has participated in another investigational trial within 4 weeks of screening~* Subject has participated in a PET research study or other study involving administration of a radioactive substance or ionizing radiation within 12 months prior to screening or has undergone an extensive radiological examination within this period~* History within 2 years prior to screening, or current evidence of a psychotic disorder or a major depressive disorder~* History of alcoholism or drug dependency/abuse within the last 2 years before screening~* History of cancer~* History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food~* Has positive test result for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV)~* Participant has had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to screening~* QTc interval ≥470 msec (for males) or ≥480 msec (for females)~* Participant consumes \>3 servings of alcohol a day~* Participant consumes \>6 caffeine servings a day~* Participant is currently a regular or recreational user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 3 months~* Suffers from claustrophobia or an inability to tolerate confinement in small places and would be unable to undergo PET or (for Part 2 only) MRI scanning~Part 1 Only:~* Evidence of a clinically relevant neurological disorder at screening~* History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological abnormality or disease~* Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies, beginning approximately 2 weeks prior to administration of the initial dose of study drug and throughout the study~Part 2 Only:~* Evidence of a clinically relevant neurological disorder other than AD at screening~* History or current evidence of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological abnormality or disease, which is not adequately controlled through a stable medication regimen~* Participant has or is suspected to have implanted or embedded metal objects, or fragments in the head or body that would present a risk during the MRI scanning procedure~* For participants undergoing arterial catheter placement only:~  * Allergy to lidocaine which may be locally injected as an anesthetic~ * Currently uses aspirin or aspirin-containing medications at doses exceeding 100 mg daily, or nonsteroidal anti-inflammatory drugs (NSAIDs), which cannot be discontinued 2 weeks prior to dosing and throughout the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Part 1, Healthy Young Participants (Type: EXPERIMENTAL): Healthy young participants received a single intravenous (IV) dose of \~185 megabecquerel (MBq) \[18F\]MK-6240 in Part 1 of the study
- Part 2, Healthy Elderly Participants (Type: EXPERIMENTAL): Healthy elderly participants received a single IV dose of \~160 MBq \[18F\]MK-6240, in Part 2 of the study
- Part 2, AD and Amnestic MCI Elderly Participants (Type: EXPERIMENTAL): AD and amnestic MCI participants received up to two IV doses of \~160 MBq \[18F\]MK-6240 in Part 2 of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete